Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval

VERTEX PHARMACEUTICALS INC / MA

2026-Q1 EPS reported $4.02 vs consensus $4.40 ▼ miss (-8.6%)

Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.
CASGEVY revenue $43M; JOURNAVX revenue $29M; non-CF products drove >25% of growth.
Completed rolling BLA submission for povetacicept in IgAN for U.S. accelerated approval; Priority Review Voucher expected to expedite review to 6 months.
Terminated VX-522 (CF) Phase 1/2 due to persistent tolerability issues; no efficacy readout possible.
FY2026 guidance reiterated: revenue $12.95-13.1B, combined R&D/SG&A unchanged.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.

Period: Q1 2026
Revenue: $2.99 billion
Net income: $1.0 billion
Result: reported results

Exact text from the filing

Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 —

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.

Period: Q1 2026
Revenue: $2.99 billion
Net income: $1.0 billion
Result: reported results

Exact text from the filing

except as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERTEX PHARMACEUTICALS INC / MA reported FY 2026 results: revenue $12.95 billion to $13.1 billion. Guidance reaffirmed.

Period: FY 2026
Revenue: $12.95 billion to $13.1 billion
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Vertex today reiterated full year 2026 financial guidance. Vertex's total revenue guidance of $12.95 billion to $13.1 billion

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-26-000171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.